title: Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.
abstract: The prognosis of almost all thyroid cancers is good, but some patients have indications for these molecularly targeted drugs. Some of these drugs, i.e., vandetanib, XL-184, sorafenib, motesanib, axitinib, and pazopanib, are clearly useful clinically.
authors.affiliation: Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan. takami@med.teikyo-u.ac.jp
authors.forename: Hiroshi E
authors.initials: HE
authors.lastname: Takami
mesh_terms: D000813:Anilides / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000627:therapeutic use; D018450:Disease Progression; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010880:Piperidines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D000077157:Sorafenib; D013964:Thyroid Neoplasms / Q000188:drug therapy*
chemical_list: D000813:Anilides; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011799:Quinazolines; C558660:cabozantinib; D009536:Niacinamide; D000077157:Sorafenib; C452423:vandetanib